SG StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceuticals & Medical Research

NaN

0.000-0.48%

Number of Gainers:2

Number of Losers:2

Number of Flat:2

PE:- -

High:NaN

Open:NaN

Low:NaN

Close:NaN

Volume:12.27M

Turnover:10.71M

Market Cap:5.93B

Float Cap:3.42B

Loading ...

IX Biopharma Ltd FY Revenue SGD 6.853 Million

THOMSON REUTERS

IX Biopharma Ltd FY Net Income SGD -7.993 Million

THOMSON REUTERS

Haw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich

Simply Wall St.

Pharmesis H1 Revenue Falls 56% Amid Challenging Operating Environment

Singapore's Medtecs HY Profit Jumps on Higher Revenue, Lower Taxes

Haw Par Corporation Hy Revenue S$115.9 Mln

THOMSON REUTERS

Haw Par 1H FY26 Net Profit Drops 25.2% to SGD 107.87 Million; Revenue Falls 8.2% to SGD 115.93 Million

Singapore's AsiaMedic HY Loss Narrows Sharply on Diagnostic Imaging Growth

Singapore's Hyphens Pharma Half-Year Profit Jumps as Margins Improve

Hyphens Pharma International Ltd H1 Revenue SGD 89.1 Million

THOMSON REUTERS

Hyphens Pharma International Ltd H1 Pretax Profit SGD 6.3 Million

THOMSON REUTERS

Hyphens Pharma International Ltd H1 Net Income SGD 4.6 Million

THOMSON REUTERS

Tianjin Pharmaceutical Unit Gets China's Nod for Diabetes Drug Registration

Tianjin Pharmaceutical Da Ren Tang to Sign Warehousing Deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK6506/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK6506","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","market":"SI","secType":"PLATE","nameCN":"Pharmaceuticals & Medical Research","latestPrice":1.5536039e-10,"timestamp":1787303474192,"preClose":1.5611523e-10,"halted":0,"volume":12272300,"delay":0,"changeRate":-0.004835,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 17:16:00 SGT","open":1.5611523e-10,"high":1.5645057e-10,"low":1.5419019e-10,"amount":10710700,"amplitude":0.014479,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787531400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787272200000,1787284800000],[1787288400000,1787303760000]],"pbRate":1.408744,"peRate":21.510392,"turnoverRate":0.010277,"increases":2,"decrements":2,"flats":3,"marketCap":5926137372,"floatMarketCap":3423124590.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","high":1.5645057e-10,"amplitude":0.014479,"preClose":1.5611523e-10,"low":1.5419019e-10,"pbRate":"1.408744","latestPrice":1.5536039e-10,"volume":12272300,"delay":0,"open":1.5611523e-10,"prevYearClose":1.4808467e-7,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0,"secType":"PLATE","market":"SI","turnoverRate":0.010277,"peRate":21.510392,"marketCap":5926137372,"floatMarketCap":3423124590.125,"timestamp":1787303474192,"nameCN":"Pharmaceuticals & Medical Research"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK6506\",,,,undefined,":{"bkCode":"BK6506","up":2,"down":2,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK6506\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661529514","title":"IX Biopharma Ltd FY Revenue SGD 6.853 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661529514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661529514?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:00","pubTimestamp":1787320839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nPLXJPXGCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","42C.SI","BK6079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295148","title":"IX Biopharma Ltd FY Net Income SGD -7.993 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661295148?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:00","pubTimestamp":1787320839,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nPLXJPXGCV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","BK6506","42C.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659179626","title":"Haw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2659179626","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659179626?lang=en_us&edition=fundamental","pubTime":"2026-08-16 04:31","pubTimestamp":1786825883,"startTime":"0","endTime":"0","summary":"Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in this half-year period is profitability. Net income of about S$107.9m on revenue of S$115.9m translates into very high margins, which matters far more than the soft share price tape.\nFor short term traders the drift in Haw Par may look uninspiring. For long term holders the focus is now on...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/sg/pharmaceuticals-biotech/sgx-h02/haw-par-shares/news/haw-par-sgxh02-stock-drifts-lower-while-margins-stay-excepti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PMDE","BK6079","DECU","VOTE","BK6506","FEBU","JOYT","SG9999006266.SGD","RGLO","GXDW","H02.SI","IE0031814969.USD","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145681","title":"Pharmesis H1 Revenue Falls 56% Amid Challenging Operating Environment","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145681","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145681?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:16","pubTimestamp":1786706173,"startTime":"0","endTime":"0","summary":"Pharmesis H1 revenue falls 56% amid challenging operating environmentOverviewPharmaceutical firm's first-half revenue fell sharply yr/yr, gross profit declined 61%Loss for the period widened sharply a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0CF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BFK.SI","BK6506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659148038","title":"Singapore's Medtecs HY Profit Jumps on Higher Revenue, Lower Taxes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659148038","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659148038?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:34","pubTimestamp":1786703688,"startTime":"0","endTime":"0","summary":"Singapore's Medtecs HY profit jumps on higher revenue, lower taxesOverviewSingapore PPE maker's half-year revenue rose 16%, while gross profit declined 3.8%Net profit for the period jumped 158% from p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["546.SI","1J5.SI","BK6079","BK6506","BK6511","BK6103","MDWD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659117668","title":"Haw Par Corporation Hy Revenue S$115.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2659117668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659117668?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:29","pubTimestamp":1786699796,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLX13WVW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","IE0031814969.USD","H02.SI","SG9999006266.SGD","BK6079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659117696","title":"Haw Par 1H FY26 Net Profit Drops 25.2% to SGD 107.87 Million; Revenue Falls 8.2% to SGD 115.93 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659117696","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659117696?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:29","pubTimestamp":1786699748,"startTime":"0","endTime":"0","summary":"Haw Par 1H FY26 net profit drops 25.2% to SGD 107.87 million; revenue falls 8.2% to SGD 115.93 millionHaw Par posted 1H 2026 net profit of SGD 107.87 million, down 25.2%, with EPS sliding to 48.7 cents.Revenue fell 8.2% to SGD 115.93 million as softer consumer sentiment weighed, with prior-year advanced orders lifting the comparative base.Other income dropped 29.9% to SGD 81.96 million on lower dividend income from strategic investments and lower interest income.Net asset value per share rose to SGD 21.43 at June 30, with strategic and long term investments up 12.0% to SGD 3.8 billion.First and interim dividend set at 20 cents a share, with payment due Sept. 11.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haw Par Corporation Ltd. pub","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2zGVVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999006266.SGD","BK6506","IE0031814969.USD","H02.SI","BK6079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659316678","title":"Singapore's AsiaMedic HY Loss Narrows Sharply on Diagnostic Imaging Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2659316678","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659316678?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:33","pubTimestamp":1786638820,"startTime":"0","endTime":"0","summary":"Singapore's AsiaMedic HY loss narrows sharply on diagnostic imaging growthOverviewSingapore healthcare provider's half-year revenue fell 2% yr/yr to S$16.2 mlnCompany's half-year loss narrowed 93% yr/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6100","BK6506","BK6027","QC7.SI","BK6079","9QX.SI","505.SI","1J5.SI","BK6511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159330","title":"Singapore's Hyphens Pharma Half-Year Profit Jumps as Margins Improve","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159330?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:21","pubTimestamp":1786620098,"startTime":"0","endTime":"0","summary":"Singapore's Hyphens Pharma half-year profit jumps as margins improveOverviewSingapore specialty pharma group's half-year revenue declined 0.5% yr/yrNet profit after tax for 1H2026 surged 132.5% yr/yrG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6506","QC7.SI","BK6079","9QX.SI","BK6100","BK6511","BK6027","1J5.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659615642","title":"Hyphens Pharma International Ltd H1 Revenue SGD 89.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659615642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659615642?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:12","pubTimestamp":1786619539,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX314C4W:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","BK6506","1J5.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659425156","title":"Hyphens Pharma International Ltd H1 Pretax Profit SGD 6.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659425156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659425156?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:12","pubTimestamp":1786619539,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX314C4W:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","1J5.SI","BK6079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156422","title":"Hyphens Pharma International Ltd H1 Net Income SGD 4.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156422?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:12","pubTimestamp":1786619539,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX314C4W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","1J5.SI","BK6506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604659","title":"Tianjin Pharmaceutical Unit Gets China's Nod for Diabetes Drug Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604659","media":"MT Newswires","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658604659?lang=en_us&edition=fundamental","pubTime":"2026-08-10 11:30","pubTimestamp":1786332601,"startTime":"0","endTime":"0","summary":"Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) said its Xinxin Pharmaceutical Plant has a drug registration certificate from China's National Medical Products Administration for a drug used to hel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tianjin Pharmaceutical Unit Gets China's Nod for Diabetes Drug Registration","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6506","BK6079","T14.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604543","title":"Tianjin Pharmaceutical Da Ren Tang to Sign Warehousing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604543","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658604543?lang=en_us&edition=fundamental","pubTime":"2026-08-10 11:24","pubTimestamp":1786332262,"startTime":"0","endTime":"0","summary":"Tianjin Pharmaceutical Da Ren Tang  intends to sign a warehousing and logistics cooperation deal with Taiping Medicine for around 19 million yuan, according to a Friday Singapore bourse filing.The traditional Chinese medicine maker's proposed arrangement will run until June 30, 2028, and will replace an expiring warehousing agreement, aimed to lowering transport costs.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6506","T14.SI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}